Intuitive Surgical (ISRG) shares experienced a notable decline on Wednesday, dropping over 4% to trade near $416.43, as the broader medical device sector faced a significant downturn. The decline followed a decision by Goldman Sachs to lower its price target on the surgical robotics company from $621 to $558, while maintaining a Buy rating. This adjustment reflects a broader trend of Wall Street trimming expectations for even strong medtech names amid market uncertainty.
The stock's performance this year has been challenging, with a decline of approximately 26%, mirroring a broader slump in medical-device equities. The iShares U.S. Medical Devices ETF (IHI) fell about 2.5% on the day, with notable declines in other large-cap names such as Medtronic (MDT), which slipped 1.7%, and Stryker (SYK), which dropped 2.4%. In contrast, the S&P 500 (SPY) edged down only 0.2%, highlighting the sector-specific headwinds.
Strong Operational Performance
Despite the stock's negative reaction, Intuitive Surgical delivered robust first-quarter results. Revenue for the quarter reached $2.77 billion, a 23% increase year-over-year, driven by strong procedure volume. The company reported approximately 847,000 da Vinci procedures, up 16% from the prior year. This growth in procedures is critical as it drives recurring sales of instruments and accessories for each surgery performed on the da Vinci system.
During the quarter, the company placed 431 da Vinci surgical systems, including 232 of the newer da Vinci 5 models. As of the end of March, the global installed base stood at about 11,395 da Vinci systems. Additionally, the Ion robotic lung-biopsy platform saw procedures rise 39% to approximately 42,700, indicating strong adoption of the company's broader product portfolio.
CEO Dave Rosa commented on the results, noting that the quarter demonstrated expanded adoption of the da Vinci, Ion, and digital platforms. The company has projected da Vinci procedure growth of 13.5% to 15.5% for the full year 2026.
Analyst Perspectives and Risks
RBC Capital analyst Shagun Singh reiterated an Outperform rating on Intuitive Surgical following the earnings release, stating that the company delivered another robust quarterly performance. Revenue and earnings surpassed consensus estimates by approximately 6% and 18%, respectively. However, Singh acknowledged that the stock's valuation remains under pressure due to sector-wide weakness.
Despite the positive operational metrics, Intuitive Surgical faces significant risks. The company has indicated that its adjusted gross margin for 2026 includes a tariff impact worth about 1% of revenue, and further tariffs could have a material adverse effect. In China, competition is intensifying, with provincial tenders increasingly favoring local players or those offering lower-cost systems. CFO Jamie Samath noted during the earnings call that competition from Chinese robotic-surgery rivals and government policies promoting systematic governance have dampened demand in that market.
Market Outlook
Investors are currently grappling with a dichotomy: Intuitive Surgical continues to show strong growth in procedures, system placements, and recurring revenue, yet the stock is being punished by a market that is reassessing valuations across the medtech space. The near-term outlook remains uncertain, with tariff risks and competitive pressures in China adding to the headwinds. As the company navigates these challenges, its ability to sustain procedure growth and margin performance will be key to restoring investor confidence.
